Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,458 total articles
Cloudflare reported Q3 revenue of $782.5M (+39%) and improved non-GAAP operating margin to 17.5%, driven by stronger usage from developers and early AI monetization. With 10M active developers and a 122% dollar-based net retention rate, the company is converting platform traction into revenue. The stock trades around $318.50 with a market cap near …
CoreWeave reported blowout Q3 revenue and a $132.5B backlog on 11/12/2026, and management raised 2026 guidance to $13.0-$13.3B. The market sold the stock over fears about leverage and interest expense; we think those concerns are already priced in and the combination of demand visibility, high pricing power and improving technicals supports a ratin…
Crescent Energy's planned $3.85B Eagle Ford purchase from Devon plus expanding royalty assets give it a rare combination: immediate free cash flow uplift, material synergy capture and a path to a capital-light growth engine. At roughly $12 a share and an EV/EBITDA near 3.65, the stock looks like a risk/reward opportunity for a mid-term trade tied t…
Energy Transfer (ET) common stock yields roughly 6.9% today, trades at a reasonable multiple (EV/EBITDA ~7.5x), and generates strong free cash flow. For income-oriented traders who like preferreds for capital protection, the common can deliver a similar yield with more upside and better liquidity if you size the position and use a tight stop. Trade…
Boeing's decision to prioritize certification quality and conservative production pacing will frustrate Wall Street in the near term, but it also reduces tail-risk from rework, regulatory blowups, and margin erosion. The company is cheap on an earnings basis but expensive versus cash generation; a measured long trade takes advantage of the market's…
First Phosphate (FRSPF) is trading near $1.17 with improving short-term momentum and unusually high short-volume. With a milestone feasibility study approaching, the setup favors a mid-term long swing that targets re-rating on positive study details or strategic partnerships. Position size should be conservative: this is an OTC exploration/early-st…
Clearfield delivered a mixed 2026: revenue softness and margin pressure late in the year weighed on the stock, but management's 2027 revenue guide of $195-205M, a 75% jump in backlog to $43.3M and a material data-center shipment de-risk near-term growth. With a market cap of roughly $425M and meaningful cash/buyback levers, this is a constructive l…
SoFi reported blowout Q3 activity with record $16.9B loan originations and lending revenues of $807.4M. The earnings print and deposit growth create a window for a mid-term swing trade. We lay out an entry at $15.70, stop at $13.80 and target at $22.00 with a 45-trading-day horizon, while flagging credit, funding-cost and valuation risks.
Municipal voters and policymakers are increasingly pushing data centers to keep their power off residential bills. Bloom Energy's on-site solid oxide fuel cells are positioned to capture that demand. Valuation is rich, but recent pullbacks and renewed data-center ordering create a mid-term buying opportunity with a clear risk-managed plan.
Molson Coors (TAP) reported weaker-than-expected Q3 results and cut full-year guidance, yet the stock remains stuck near $40 and displays textbook value traps in cyclical, commodity-exposed businesses. With sales and EPS guidance now pointing down and margin compression still ongoing, I favor a tactical short over the next 45 trading days. Entry $4…
Aveanna Healthcare has delivered four straight quarters of beats, most recently reporting Q3 revenue of $695.54M and EPS of $0.23 on 11/12/2026. The business is scaling, free cash flow is positive, and the stock has already rallied YTD. Yet today's pullback has created a mid-term trade opportunity: buy on weakness into $12.30 with a stop at $10.50 …
Taiwan Semiconductor (TSM) is uniquely positioned to absorb near-term shocks thanks to deep customer relationships, high margins, and constrained supply of advanced nodes. Valuation at ~26.6x earnings and a $2.10 trillion market cap discounts a lot of growth, leaving room for 15-20% upside on normalization. This trade idea outlines a clear entry, s…
Jensen Huang's resignation creates a tangible leadership premium risk for Nvidia that the market has not fully priced. The business remains structurally strong, but near-term sentiment, governance scrutiny, and potential contract fallout argue for a downgrade and a tactical short. Entry, stop and target provided for a mid-term (45 trading days) tra…
Intel's share price has been materially repriced. The business still produces positive free cash flow, carries manageable net leverage, and sits at the center of secular AI and foundry cycles. We upgrade to Strong Buy and recommend a position-sized long for patient, risk-aware traders looking for a rebound over the next 3-6 months.
Pfizer's announcement that Blackstone Life Sciences will provide up to $1.5 billion to fund berobenatide Phase III studies is a headline event, but it should not be interpreted as a guarantee of success. The market appears to be extrapolating an obesity win into Pfizer's valuation; we think that's premature. We recommend a mid-term (45 trading days…
La-Z-Boy shares pulled back to the low $30s after an earnings-driven volatility swing. The business generates healthy free cash flow, trades at a modest multiple and benefits from a retail mix that can sustain margins over time. This trade idea lays out an actionable entry, stop and target for a mid-term swing while flagging the main risks that cou…
Nvidia plunged after CEO Jensen Huang resigned on 11/12/2026, but the company’s underlying economics - dominant data-center GPU share, massive free cash flow, and strong returns on capital - remain intact. This trade idea outlines a mid-term long with entry at $166.23, stop at $148.80 and a target of $205.00 over a 45 trading day horizon.
PepGen has meaningful upside if the recently signaled improvement in PGN-EDODM1 splicing data holds and the company meets its 2027 program milestones. Market cap is modest relative to potential program value, balance sheet and technical momentum support an opportunistic long. This is a high-risk, high-reward biotech trade with clearly defined entry…
Kimberly-Clark (KMB) combines a high dividend yield, newly acquired consumer health brands, and a clear cost-synergy plan. With a market cap near $65.9B, free cash flow of $1.94B and a $1.9B synergy target from the Kenvue deal, KMB offers a risk-reward that favors a long position into 2027 as volumes and pricing stabilize.
Intuitive Surgical reported strong procedure and revenue growth despite a $450 million no-fault settlement that trimmed GAAP EPS. I remain constructive on ISRG because the core Da Vinci and Ion franchises keep compounding revenue and free cash flow, but I have trimmed my price target to reflect the settlement and current valuation. This trade idea …
Shiseido’s recent beat-and-raise narrative and improving technicals suggest the company is moving past a restructuring trough. At a $10.2B market cap and trading near $25.50, the stock offers a tactical mid-term long with defined risk management: entry $25.50, stop $23.00, target $29.00 (mid term - 45 trading days). Key drivers include improving pr…
Apnimed's oral AD109 aims to be the first convenient pill to treat obstructive sleep apnea (OSA). With two Phase 3 trials completed, a PDUFA goal date on 02/28/2027 and $220.8M raised in an August IPO, the stock at roughly $16.68 and a market cap near $694M is an asymmetric risk-reward for long-term traders who can tolerate biotech binary risk.
Travel + Leisure (TNL) shows improving credit performance in its vacation ownership business, healthy free cash flow generation, and incremental earnings upside from recent acquisitions. Those fundamentals, combined with bullish technicals, support a tactical long trade with a mid-term horizon of 45 trading days.
First Solar is trading near the low end of its recent range after a guidance cut and mixed booking commentary, yet the stock still sports a modest valuation (P/E ~10.3) and a 44 GW backlog. With Democrats in control and Section 232 protections leaning toward domestic suppliers, the next 45 trading days should favor selective upside. This is a tacti…
Beam Therapeutics reported data that met primary efficacy and safety endpoints in its BEACON sickle cell study yet shares fell on the news. With a $2.57B market cap, a deep short base, and multiple near-term catalysts including a planned BLA submission, the risk/reward favors a tactical long. This trade lays out entry, stop and targets across a mid…
